{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:54:29Z","timestamp":1773330869416,"version":"3.50.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:00:00Z","timestamp":1496361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s10620-017-4633-8","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T04:29:52Z","timestamp":1496377792000},"page":"2999-3013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis"],"prefix":"10.1007","volume":"62","author":[{"given":"Klaus","family":"Bielefeldt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"key":"4633_CR1","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1053\/j.gastro.2005.11.059","volume":"130","author":"J Tack","year":"2006","unstructured":"Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466\u20131479.","journal-title":"Gastroenterology"},{"key":"4633_CR2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12875-016-0460-9","volume":"17","author":"PF Haastrup","year":"2016","unstructured":"Haastrup PF, Rasmussen S, Hansen JM, et al. General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study. BMC Fam Pract. 2016;17:57.","journal-title":"BMC Fam Pract"},{"key":"4633_CR3","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/gutjnl-2011-301898","volume":"61","author":"PJ Kahrilas","year":"2012","unstructured":"Kahrilas PJ, Boeckxstaens G. Failure of reflux inhibitors in clinical trials: Bad drugs or wrong patients? Gut. 2012;61:1501\u20131509.","journal-title":"Gut"},{"key":"4633_CR4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaip.2014.11.009","volume":"3","author":"M Chehade","year":"2015","unstructured":"Chehade M, Aceves SS, Furuta GT, et al. Food allergy and eosinophilic esophagitis: What do we do? J Allergy Clin Immunol Pract. 2015;3:25\u201332.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4633_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MED.0000000000000031","volume":"21","author":"VD Corleto","year":"2014","unstructured":"Corleto VD, Festa S, Di Giulio E, et al. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diab Obes. 2014;21:3\u20138.","journal-title":"Curr Opin Endocrinol Diab Obes"},{"key":"4633_CR6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40266-014-0166-4","volume":"31","author":"GM Masclee","year":"2014","unstructured":"Masclee GM, Sturkenboom MC, Kuipers EJ. A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging. 2014;31:263\u2013282.","journal-title":"Drugs Aging"},{"key":"4633_CR7","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1053\/j.gastro.2015.04.020","volume":"149","author":"NJ Talley","year":"2015","unstructured":"Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015;149:e2.","journal-title":"Gastroenterology"},{"key":"4633_CR8","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1001\/jama.2013.282833","volume":"310","author":"HP Parkman","year":"2013","unstructured":"Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA. 2013;310:2640\u20132649.","journal-title":"JAMA"},{"key":"4633_CR9","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/nmo.12064","volume":"25","author":"N Ejskjaer","year":"2013","unstructured":"Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013;25:e140\u2013e150.","journal-title":"Neurogastroenterol Motil"},{"key":"4633_CR10","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1111\/nmo.12184","volume":"25","author":"RW McCallum","year":"2013","unstructured":"McCallum RW, Lembo A, Esfandyari T, et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013;25:e705\u2013e717.","journal-title":"Neurogastroenterol Motil"},{"key":"4633_CR11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2036.2007.03346.x","volume":"26","author":"RW McCallum","year":"2007","unstructured":"McCallum RW, Cynshi O, Team UI. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther. 2007;26:107\u2013116.","journal-title":"Aliment Pharmacol Ther"},{"key":"4633_CR12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1365-2036.2007.03461.x","volume":"15","author":"RW McCallum","year":"2007","unstructured":"McCallum RW, Cynshi O, Team I. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis\u2014a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther. 2007;15:1121\u20131130.","journal-title":"Aliment Pharmacol Ther"},{"key":"4633_CR13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.cgh.2008.02.051","volume":"6","author":"LAS Kerkhoven van","year":"2008","unstructured":"van Kerkhoven LAS, Laheij RJF, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2008;6:746\u2013752.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4633_CR14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1331\/1544345042467191","volume":"44","author":"D Shaffer","year":"2004","unstructured":"Shaffer D, Butterfield M, Pamer C, et al. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc. 2004;44:661\u2013665.","journal-title":"J Am Pharm Assoc"},{"key":"4633_CR15","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/j.1572-0241.2001.03927.x","volume":"96","author":"DK Wysowski","year":"2001","unstructured":"Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions. Am J Gastroenterol. 2001;96:1698\u20131703.","journal-title":"Am J Gastroenterol"},{"key":"4633_CR16","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1053\/j.gastro.2007.04.057","volume":"132","author":"P Pasricha","year":"2007","unstructured":"Pasricha P. Desperately seeking serotonin\u2026 A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology. 2007;132:2287\u20132290.","journal-title":"Gastroenterology"},{"key":"4633_CR17","first-page":"60169","volume":"81","author":"Food and Drug Administration","year":"2016","unstructured":"Food and Drug Administration. Requirements for foreign and domestic establishment registration and listing for human drugs, including drugs that are regulated under a biologics license application, and animal drugs. Final rule. Fed Regist. 2016;81:60169\u201360224.","journal-title":"Fed Regist"},{"key":"4633_CR18","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1503\/cmaj.1040882","volume":"170","author":"E Wooltorton","year":"2004","unstructured":"Wooltorton E. Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. CMAJ. 2004;170:1908.","journal-title":"CMAJ"},{"key":"4633_CR19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s10620-014-3144-0","volume":"59","author":"K Bielefeldt","year":"2014","unstructured":"Bielefeldt K. From ischochymia to gastroparesis: proposed mechanisms and preferred management of dyspepsia over the centuries. Dig Dis Sci. 2014;59:1088\u20131098.","journal-title":"Dig Dis Sci"},{"key":"4633_CR20","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2013-306084","volume":"63","author":"V Stanghellini","year":"2014","unstructured":"Stanghellini V, Tack J. Gastroparesis: Separate entity or just a part of dyspepsia? Gut. 2014;63:1972\u20131978.","journal-title":"Gut"},{"key":"4633_CR21","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/ajg.2013.118","volume":"108","author":"P Janssen","year":"2013","unstructured":"Janssen P, Scott Harris M, Jones M, et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol. 2013;108:1382\u20131391.","journal-title":"Am J Gastroenterol"},{"key":"4633_CR22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1517\/14740338.2016.1173204","volume":"15","author":"I Sarosiek","year":"2016","unstructured":"Sarosiek I, Bashashati M, McCallum RW. Safety of treatment for gastroparesis. Expert Opin Drug Saf. 2016;15:937\u2013945.","journal-title":"Expert Opin Drug Saf"},{"key":"4633_CR23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ajg.2012.300","volume":"108","author":"ED Ehrenpreis","year":"2013","unstructured":"Ehrenpreis ED, Deepak P, Sifuentes H, et al. The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol. 2013;108:866\u2013872.","journal-title":"Am J Gastroenterol"},{"key":"4633_CR24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000445226","volume":"34","author":"M Camilleri","year":"2016","unstructured":"Camilleri M. Functional dyspepsia and gastroparesis. Dig Dis. 2016;34:491\u2013499.","journal-title":"Dig Dis"},{"key":"4633_CR25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s11938-015-0071-x","volume":"13","author":"X Zhao","year":"2015","unstructured":"Zhao X, Mashimo H. Current and emerging medical therapies for gastroparesis. Curr Treat Options Gastroenterol. 2015;13:452\u2013472.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"4633_CR26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gtc.2014.11.005","volume":"44","author":"KL Koch","year":"2015","unstructured":"Koch KL, Calles-Escandon J. Diabetic gastroparesis. Gastroenterol Clin North Am. 2015;44:39\u201357.","journal-title":"Gastroenterol Clin North Am"},{"key":"4633_CR27","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1007\/s10620-014-3369-y","volume":"59","author":"A Dudekula","year":"2014","unstructured":"Dudekula A, Rahim S, Bielefeldt K. Time trends in gastroparesis treatment. Dig Dis Sci. 2014;59:2656\u20132665.","journal-title":"Dig Dis Sci"},{"key":"4633_CR28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2012.373","volume":"108","author":"M Camilleri","year":"2013","unstructured":"Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108:18\u201337.","journal-title":"Am J Gastroenterol"},{"key":"4633_CR29","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14656566.2013.809063","volume":"14","author":"B Moshiree","year":"2013","unstructured":"Moshiree B, Barboza J, Talley N. An update on current pharmacotherapy options for dyspepsia. Exp Opin Pharmacother. 2013;14:1737\u20131753.","journal-title":"Exp Opin Pharmacother"},{"key":"4633_CR30","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.cgh.2011.03.003","volume":"9","author":"PJ Pasricha","year":"2011","unstructured":"Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol. 2011;9:e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4633_CR31","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.cgh.2011.08.013","volume":"9","author":"HP Parkman","year":"2011","unstructured":"Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:1056\u20131064.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4633_CR32","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1023\/A:1026665728213","volume":"43","author":"I Soykan","year":"1998","unstructured":"Soykan I, Sivri B, Sarosiek I, et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Digest Dis Sci. 1998;43:2398\u20132404.","journal-title":"Digest Dis Sci"},{"key":"4633_CR33","doi-asserted-by":"crossref","first-page":"1088\u2013e565","DOI":"10.1111\/j.1365-2982.2012.01985.x","volume":"24","author":"N Clauwaert","year":"2012","unstructured":"Clauwaert N, Jones MP, Holvoet L, et al. Associations between gastric sensorimotor function, depression, somatization, and symptom-based subgroups in functional gastroduodenal disorders: Are all symptoms equal? Neurogastroenterol Motil. 2012;24:1088\u2013e565.","journal-title":"Neurogastroenterol Motil"},{"key":"4633_CR34","doi-asserted-by":"publisher","first-page":"424802","DOI":"10.6064\/2012\/424802","volume":"2012","author":"K Bielefeldt","year":"2012","unstructured":"Bielefeldt K. Gastroparesis: concepts, controversies, and challenges. Scientifica (Cairo). 2012;2012:424802. doi: 10.6064\/2012\/424802 .","journal-title":"Scientifica (Cairo)"},{"key":"4633_CR35","unstructured":"Food and Drug Administration. Medication Guide: Reglan. https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM176362.pdf ."},{"key":"4633_CR36","first-page":"1230","volume":"94","author":"D Patterson","year":"1999","unstructured":"Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94:1230\u20131234.","journal-title":"Am J Gastroenterol"},{"key":"4633_CR37","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/AOG.0000000000000242","volume":"123","author":"MN Abas","year":"2014","unstructured":"Abas MN, Tan PC, Azmi N, et al. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol. 2014;123:1272\u20131279.","journal-title":"Obstet Gynecol"},{"key":"4633_CR38","unstructured":"Jackson I. Reglan settlement reportedly reached for tardive dyskinesia lawsuits. https:\/\/www.aboutlawsuits.com\/reglan-settlement-proposed-119910 ."},{"key":"4633_CR39","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/pds.3329","volume":"21","author":"CE Leonard","year":"2012","unstructured":"Leonard CE, Freeman CP, Newcomb CW, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012;21:1155\u20131172.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4633_CR40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2369-14-150","volume":"14","author":"DG Klepser","year":"2013","unstructured":"Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case\u2013control study. BMC Nephrol. 2013;14:150.","journal-title":"BMC Nephrol"},{"key":"4633_CR41","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ndt\/gfu326","volume":"30","author":"M Praga","year":"2015","unstructured":"Praga M, Sevillano A, Aunon P, et al. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant. 2015;30:1472\u20131479.","journal-title":"Nephrol Dial Transplant"},{"key":"4633_CR42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238\u2013246.","journal-title":"JAMA Intern Med"},{"key":"4633_CR43","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1681\/ASN.2015121377","volume":"27","author":"Y Xie","year":"2016","unstructured":"Xie Y, Bowe B, Li T, et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27:3153\u20133163.","journal-title":"J Am Soc Nephrol"},{"key":"4633_CR44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","volume":"179","author":"LE Targownik","year":"2008","unstructured":"Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Cmaj. 2008;179:319\u2013326.","journal-title":"Cmaj"},{"key":"4633_CR45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","volume":"79","author":"P Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76\u201383.","journal-title":"Calcif Tissue Int"},{"key":"4633_CR46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00223-008-9188-4","volume":"84","author":"C Roux","year":"2009","unstructured":"Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 2009;84:13\u201319.","journal-title":"Calcif Tissue Int"},{"key":"4633_CR47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jat\/15.2.101","volume":"15","author":"A Poklis","year":"1991","unstructured":"Poklis A, Hall KV, Still J, et al. Ranitidine interference with the monoclonal EMIT d.a.u. amphetamine\/methamphetamine immunoassay. J Anal Toxicol. 1991;15:101\u2013103.","journal-title":"J Anal Toxicol"},{"key":"4633_CR48","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cgh.2006.09.012","volume":"5","author":"WH Wang","year":"2007","unstructured":"Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007;5:178\u2013185. (quiz 140).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4633_CR49","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1046\/j.1365-2036.2001.01044.x","volume":"15","author":"HA Redstone","year":"2001","unstructured":"Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther. 2001;15:1291\u20131299.","journal-title":"Aliment Pharmacol Ther"},{"key":"4633_CR50","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa1204410","volume":"367","author":"JC Weeks","year":"2012","unstructured":"Weeks JC, Catalano PJ, Cronin A, et al. Patients\u2019 expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367:1616\u20131625.","journal-title":"N Engl J Med"},{"key":"4633_CR51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1164\/rccm.201505-0882OC","volume":"193","author":"JL Hart","year":"2016","unstructured":"Hart JL, Pflug E, Madden V, et al. Thinking forward: future-oriented thinking among patients with tobacco-associated thoracic diseases and their surrogates. Am J Respir Crit Care Med. 2016;193:321\u2013329.","journal-title":"Am J Respir Crit Care Med"},{"key":"4633_CR52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MCG.0000000000000543","volume":"51","author":"ED Ehrenpreis","year":"2017","unstructured":"Ehrenpreis ED, Roginsky G, Alexoff A, et al. Domperidone is commonly prescribed with QT-interacting drugs: review of a community-based practice and a postmarketing adverse drug event reporting database. J Clin Gastroenterol. 2017;51:56\u201362.","journal-title":"J Clin Gastroenterol"},{"key":"4633_CR53","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/phar.1832","volume":"36","author":"KW McConeghy","year":"2016","unstructured":"McConeghy KW, Soriano MM, Danziger LH. A quantitative analysis of FDA adverse event reports with oral bisphosphonates and clostridium difficile. Pharmacotherapy. 2016;36:1095\u20131101.","journal-title":"Pharmacotherapy"},{"key":"4633_CR54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1078155215621150","volume":"23","author":"S Wittayanukorn","year":"2017","unstructured":"Wittayanukorn S, Qian J, Johnson BS, et al. Cardiotoxicity in targeted therapy for breast cancer: a study of the FDA adverse event reporting system (FAERS). J Oncol Pharm Pract. 2017;23:93\u2013102.","journal-title":"J Oncol Pharm Pract"},{"key":"4633_CR55","doi-asserted-by":"crossref","first-page":"427\u2013e301","DOI":"10.1111\/nmo.12091","volume":"25","author":"WL Hasler","year":"2013","unstructured":"Hasler WL, Wilson LA, Parkman HP, et al. Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterol Motil. 2013;25:427\u2013e301.","journal-title":"Neurogastroenterol Motil"},{"key":"4633_CR56","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cgh.2014.12.030","volume":"13","author":"HP Parkman","year":"2015","unstructured":"Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study. Clin Gastroenterol Hepatol. 2015;13:e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4633_CR57","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/nmo.12296","volume":"26","author":"HP Parkman","year":"2014","unstructured":"Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. Neurogastroenterol Motil. 2014;26:521\u2013528.","journal-title":"Neurogastroenterol Motil"},{"key":"4633_CR58","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2337\/diacare.6.5.463","volume":"6","author":"R McCallum","year":"1983","unstructured":"McCallum R, Ricci D, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabet Care. 1983;6:463\u2013467.","journal-title":"Diabet Care"},{"key":"4633_CR59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004836-198502000-00003","volume":"7","author":"DA Ricci","year":"1985","unstructured":"Ricci DA, Saltzman MB, Meyer C, et al. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7:25\u201332.","journal-title":"J Clin Gastroenterol"},{"key":"4633_CR60","first-page":"e10","volume":"140","author":"HP Parkman","year":"2011","unstructured":"Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology. 2011;140:e10.","journal-title":"Gastroenterology"},{"key":"4633_CR61","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10620-017-4456-7","volume":"62","author":"D Yu","year":"2017","unstructured":"Yu D, Ramsey FV, Norton WF, et al. The burdens, concerns, and quality of life of patients with gastroparesis. Dig Dis Sci. 2017;62:879\u2013893.","journal-title":"Dig Dis Sci"},{"key":"4633_CR62","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10620-014-3097-3","volume":"59","author":"K Simmons","year":"2014","unstructured":"Simmons K, Parkman H. Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis. Dig Dis Sci. 2014;59:1231\u20131234.","journal-title":"Dig Dis Sci"},{"key":"4633_CR63","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2982.2007.00988.x","volume":"19","author":"V Dizdar","year":"2007","unstructured":"Dizdar V, Gilja OH, Hausken T. Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron. Neurogastroenterol Motil. 2007;19:977\u2013982.","journal-title":"Neurogastroenterol Motil"},{"key":"4633_CR64","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.dld.2007.11.013","volume":"40","author":"L Marzio","year":"2008","unstructured":"Marzio L, Cappello G, Grossi L, et al. Effect of the 5-HT3 receptor antagonist, ondansetron, on gastric size in dyspeptic patients with impaired gastric accommodation. Dig Liver Dis. 2008;40:188\u2013193.","journal-title":"Dig Liver Dis"},{"key":"4633_CR65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, et al. 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25:277\u2013288.","journal-title":"Support Care Cancer"},{"key":"4633_CR66","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3413\/Nukmed-0654-14-03","volume":"53","author":"M Mirzababaee","year":"2014","unstructured":"Mirzababaee M, Shafiei B, Seifollahi S, et al. Management of gastrointestinal complaints in differentiated thyroid cancer patients treated with (131)I: comparison of the efficacy of pantoprazole, metoclopramide, and ondansetron\u2014a randomized clinical trial. Nuklearmedizin. 2014;53:186\u2013189.","journal-title":"Nuklearmedizin"},{"key":"4633_CR67","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1742-6723.2011.01444.x","volume":"23","author":"J Chae","year":"2011","unstructured":"Chae J, Taylor DM, Frauman AG. Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: a randomized, double-blinded, clinical trial. Emerg Med Australas. 2011;23:554\u2013561.","journal-title":"Emerg Med Australas"},{"key":"4633_CR68","first-page":"2064","volume":"59","author":"S Wu","year":"2012","unstructured":"Wu S, Xiong X, Cheng T, et al. Efficacy of ondansetron vs. metoclopramide in prophylaxis of postoperative nausea and vomiting after laparoscopic cholecystectomy: a systematic review and meta-analysis. Hepatogastroenterology. 2012;59:2064\u20132074.","journal-title":"Hepatogastroenterology"},{"key":"4633_CR69","first-page":"127","volume":"40","author":"M Kashifard","year":"2013","unstructured":"Kashifard M, Basirat Z, Kashifard M, et al. Ondansetrone or metoclopromide? Which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study. Clin Exp Obstet Gynecol. 2013;40:127\u2013130.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"4633_CR70","first-page":"165","volume":"79","author":"RW McCallum","year":"1984","unstructured":"McCallum RW, Fink SM, Winnan GR, et al. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial. Am J Gastroenterol. 1984;79:165\u2013172.","journal-title":"Am J Gastroenterol"},{"key":"4633_CR71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-104-1-21","volume":"104","author":"DA Lieberman","year":"1986","unstructured":"Lieberman DA, Keeffe EB. Treatment of severe reflux esophagitis with cimetidine and metoclopramide. Ann Intern Med. 1986;104:21\u201326.","journal-title":"Ann Intern Med"},{"key":"4633_CR72","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00005176-198607000-00008","volume":"5","author":"D Forbes","year":"1986","unstructured":"Forbes D, Hodgson M, Hill R. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr. 1986;5:556\u2013559.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4633_CR73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-3476(89)80351-8","volume":"115","author":"V Tolia","year":"1989","unstructured":"Tolia V, Calhoun J, Kuhns L, et al. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. J Pediatr. 1989;115:141\u2013145.","journal-title":"J Pediatr"},{"key":"4633_CR74","first-page":"697","volume":"85","author":"WC Orr","year":"1990","unstructured":"Orr WC, Finn A, Wilson T, et al. Esophageal acid contact time and heartburn in acute treatment with ranitidine and metoclopramide. Am J Gastroenterol. 1990;85:697\u2013700.","journal-title":"Am J Gastroenterol"},{"key":"4633_CR75","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/BF01307583","volume":"37","author":"L Grande","year":"1992","unstructured":"Grande L, Lacima G, Ros E, et al. Lack of effect of metoclopramide and domperidone on esophageal peristalsis and esophageal acid clearance in reflux esophagitis. A randomized, double-blind study. Dig Dis Sci. 1992;37:583\u2013588.","journal-title":"Dig Dis Sci"},{"key":"4633_CR76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2036.1993.tb00071.x","volume":"7","author":"M Robinson","year":"1993","unstructured":"Robinson M, Decktor DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther. 1993;7:67\u201373.","journal-title":"Aliment Pharmacol Ther"},{"key":"4633_CR77","first-page":"1766","volume":"91","author":"JE Richter","year":"1996","unstructured":"Richter JE, Sabesin SM, Kogut DG, et al. Omeprazole versus ranitidine or ranitidine\/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 1996;91:1766\u20131772.","journal-title":"Am J Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-017-4633-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4633-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4633-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T14:19:30Z","timestamp":1719238770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-017-4633-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["4633"],"URL":"https:\/\/doi.org\/10.1007\/s10620-017-4633-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,2]]}}}